WASHINGTON–(BUSINESS WIRE)–#Parkinsons–RightEye LLC announces acquisition of new tests to enable early identification of autism in toddlers and Parkinson’s disease in patients of all ages.
FDA approves VisuMax Femtosecond Laser to surgically treat nearsightedness
The U.S. Food and Drug Administration has approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain…
Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported the successful 90-day primary efficacy results of its 12-month Phase 3 “Mercury 1” clinical trial for its fixed-dose combination product candidate, RoclatanTM. The study achieved its primary efficacy endpoint demonstra
Uncategorized
Nanosecond laser may be safe for cataract surgery at a lower cost than femtosecond laser
COPENHAGEN — Nanosecond laser may represent an affordable, safe and effective way of doing laser cataract surgery, according to one speaker.“A minimal level of energy is applied to the eye. There is no thermal alteration in the anterior chamber, no mechanical or thermal side effects,” Jérôme C. Vryghem, MD, said at the European Society of Cataract and Refractive Surgeons meeting.
Research findings hold promise for new therapies using proliferating cells to treat patients with FECD
Researchers from Massachusetts Eye and Ear have, for the first time, identified rapidly proliferating cells (known as “neural crest-derived progenitor cells”) in the corneal endothelium of specimens from normal corneas and from corneas with Fuchs’ Endothelial Corneal Dystrophy (FECD), a condition in which the cells responsible for keeping the cornea clear die prematurely — often leading to blindness.
Uncategorized
VIDEO: Visual results maintained at 12 months in PiXL for low myopia
COPENHAGEN — At the European Society of Cataract and Refractive Surgeons meeting here, Matthias Elling, MD, discussed the results of a prospective clinical trial of PiXL, or photorefractive intrastromal cross-linking, conducted in Germany using an epi-off technique for the correction of myopia up to –3 D.